Bear of the Day: Carter's (CRI)

Carter's (CRI) is facing significant operational and financial pressure, marked by a 4.8% year-over-year sales decline in Q1 2025 across all segments and weakened margins, alongside persistent macroeconomic headwinds and tariff challenges. Analyst sentiment has deteriorated sharply, leading to substantial downward revisions in earnings estimates, including a 13.6% cut for 2026 projections, culminating in a Zacks Rank #5 (Strong Sell) rating. With a sluggish sales outlook and limited visibility for a turnaround, CRI's stock is underperforming and appears poised for continued pressure, suggesting investors may prefer to avoid it.

Analysis

Carter's Inc. (CRI) is facing significant fundamental pressure, underscored by a broad-based decline in its first-quarter 2025 sales, which fell 4.8% year-over-year. The weakness was consistent across all key segments, with US Retail down 4.3%, US Wholesale down 5.3%, and International down 4.9%, indicating systemic demand issues rather than isolated weakness. This top-line deterioration has directly impacted profitability, with lower volumes contributing to a 140 basis point contraction in gross margin and a severe 35.7% drop in operating income. These internal challenges are compounded by a difficult macroeconomic environment, including inflation, high interest rates, and ongoing tariff uncertainty, which particularly affects Carter's due to its reliance on Asian production. The market's forward-looking sentiment has soured considerably, as reflected in substantial downward revisions to earnings estimates. Analyst forecasts for the current quarter have been cut by 13.3%, and the projection for 2026 earnings has been slashed by 13.6%, culminating in a Zacks Rank #5 (Strong Sell) rating. The outlook remains bleak, with sales expected to fall 1.7% in 2025 before a negligible 0.9% recovery in 2026, suggesting limited prospects for a near-term turnaround and supporting the stock's continued underperformance.

Key Decisions for Investors

• Given the accelerating downward earnings revisions and a Zacks #5 (Strong Sell) rating, investors should view the stock with extreme caution and consider reducing exposure, as near-term catalysts for a positive re-rating appear absent.
• The combination of broad-based sales declines, significant margin compression, and persistent macroeconomic headwinds makes CRI a potential candidate for a short position or a stock to avoid in a long-only portfolio.
• A potential turnaround would require clear evidence of a reversal in sales trends and margin stabilization; the currently projected 0.9% sales rebound in 2026 is too weak to justify a long position at this time.
• Monitor consumer confidence indicators and any developments regarding tariffs on goods from Asia, as these external factors represent significant ongoing risks to CRI's profitability and revenue.